Prime Medicine (PRME) news
Recent news
Prime Medicine: Initial clinical data from PM577A trial expected in 2027
Prime Medicine (Nasdaq: PRME) has announced that initial clinical data from its PM577A trial is expected in 2027, according to the company’s recent communications about PM577A . This update comes amid continued progress in the company’s liver-focused therapeutic pipeline, which includes PM577A, an…
AInvest Wire · 7d agoPrime Medicine, - PM577 granted rare pediatric disease designation by U.S. FDA
AInvest Wire · 7d agoPrime Medicine jumps more than 10% on FDA study clearance
Shares of Prime Medicine rose more than 10% following news that the U.S. Food and Drug Administration has cleared an investigational study related to the company’s gene therapy programs. The FDA clearance marks a key regulatory milestone, enabling the firm to advance its clinical development…
AInvest Wire · Sep 24, 2026Prime Medicine: Initial clinical data for PM647 expected in 2027
AInvest Wire · Sep 24, 2026Prime Medicine announces U.S. FDA clearance of investigational new drug application for PM647 in alpha-1 antitrypsin deficiency
AInvest Wire · Sep 24, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.